The methylation of TXNRD2 with chronic heart failure: the interaction effect between methylation regulation and clinical parameters-- a single center pilot study

This study investigated the potential role of TXNRD2_FA44 promoter methylation in chronic heart failure (CHF) and its influence on disease mechanisms. Additionally, we explored the association between specific Cytosine-phosphate-Guanine (CpG) site methylation levels within the TXNRD2_FA44 promoter and various biochemical markers in CHF patients. The study included 20 individuals suffering from chronic heart failure and an equal number of healthy participants. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF–MS), CpG sites in the TXNRD2_FA44 promoter region were pinpointed and measured. The comparison of methylation levels was conducted between CHF patients and healthy individuals. Statistics was used to analyze the relationship between TXNRD2_FA44_CpG_27.28.29 and various key biochemical indicators. Patients with CHF exhibited significantly higher methylation levels at TXNRD2_FA44_CpG_27.28.29 compared to controls (P = 0.0008). This elevated methylation level correlated with levels of creatinine (Crea), estimated glomerular filtration rate (eGFR), percentage of lymphocytes (LYMPH), albumin (ALB), globulin (GLB), and the albumin-to-globin ratio (A/G) in CHF patients. The methylation level of TXNRD2-FA44 in patients with chronic heart failure is significantly higher than controls, and the methylation level of TXNRD2-FA44 is related to multiple liver and kidney function indicators. These findings suggest that TXNRD2-FA44 could serve as a biomarker for CHF diagnosis and may affect the occurrence and development of CHF through liver and kidney function.